Chemomab Total Assets from 2010 to 2026

CMMB Stock  USD 1.51  0.03  2.03%   
Chemomab Therapeutics' Total Assets are increasing over the years with slightly volatile fluctuation. Overall, Total Assets are expected to go to about 21.2 M this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals
 
Total Assets  
First Reported
2012-09-30
Previous Quarter
11.1 M
Current Value
12.4 M
Quarterly Volatility
22.4 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Chemomab Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chemomab Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.4 K, Other Operating Expenses of 12.4 M or Research Development of 12.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.53. Chemomab financial statements analysis is a perfect complement when working with Chemomab Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Chemomab Stock
Check out the analysis of Chemomab Therapeutics Correlation against competitors.
Analyzing Chemomab Therapeutics's Total Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Assets has evolved provides context for assessing Chemomab Therapeutics's current valuation and future prospects.

Latest Chemomab Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Chemomab Therapeutics Ltd over the last few years. Total assets refers to the total amount of Chemomab Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Chemomab Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Chemomab Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Chemomab Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 16.96 M10 Years Trend
Slightly volatile
   Total Assets   
       Timeline  

Chemomab Total Assets Regression Statistics

Arithmetic Mean16,411,311
Geometric Mean11,103,435
Coefficient Of Variation97.29
Mean Deviation10,840,158
Median12,476,000
Standard Deviation15,965,997
Sample Variance254.9T
Range62.3M
R-Value0.52
Mean Square Error197.6T
R-Squared0.27
Significance0.03
Slope1,652,423
Total Sum of Squares4078.6T

Chemomab Total Assets History

202621.2 M
202519.5 M
202417 M
202322.2 M
202243.1 M
202164.4 M
202012.5 M

Other Fundumenentals of Chemomab Therapeutics

Chemomab Therapeutics Total Assets component correlations

0.99-0.730.150.750.020.291.00.480.960.980.980.770.74-0.09-0.68-0.12
0.99-0.680.210.770.010.170.990.50.970.980.990.770.74-0.09-0.69-0.11
-0.73-0.68-0.36-0.28-0.15-0.38-0.72-0.51-0.52-0.66-0.67-0.28-0.55-0.130.43-0.09
0.150.21-0.360.06-0.06-0.60.150.310.10.20.2-0.220.060.280.070.44
0.750.77-0.280.06-0.030.110.750.290.820.770.770.740.57-0.1-0.64-0.17
0.020.01-0.15-0.06-0.030.00.00.26-0.09-0.1-0.07-0.1-0.160.030.140.09
0.290.17-0.38-0.60.110.00.29-0.080.160.20.190.220.13-0.05-0.21-0.11
1.00.99-0.720.150.750.00.290.470.960.980.980.770.73-0.09-0.68-0.11
0.480.5-0.510.310.290.26-0.080.470.40.50.510.470.7-0.09-0.61-0.42
0.960.97-0.520.10.82-0.090.160.960.40.970.970.850.71-0.21-0.7-0.17
0.980.98-0.660.20.77-0.10.20.980.50.971.00.820.77-0.17-0.71-0.19
0.980.99-0.670.20.77-0.070.190.980.510.971.00.820.76-0.17-0.71-0.19
0.770.77-0.28-0.220.74-0.10.220.770.470.850.820.820.81-0.46-0.84-0.65
0.740.74-0.550.060.57-0.160.130.730.70.710.770.760.81-0.34-0.95-0.62
-0.09-0.09-0.130.28-0.10.03-0.05-0.09-0.09-0.21-0.17-0.17-0.46-0.340.40.56
-0.68-0.690.430.07-0.640.14-0.21-0.68-0.61-0.7-0.71-0.71-0.84-0.950.40.63
-0.12-0.11-0.090.44-0.170.09-0.11-0.11-0.42-0.17-0.19-0.19-0.65-0.620.560.63
Click cells to compare fundamentals

About Chemomab Therapeutics Financial Statements

Chemomab Therapeutics stakeholders use historical fundamental indicators, such as Chemomab Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Although Chemomab Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Chemomab Therapeutics' assets and liabilities are reflected in the revenues and expenses on Chemomab Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Chemomab Therapeutics Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Assets19.5 M21.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock:
Check out the analysis of Chemomab Therapeutics Correlation against competitors.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. Projected growth potential of Chemomab fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Chemomab Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.44)
Return On Assets
(0.41)
Return On Equity
(0.73)
Chemomab Therapeutics's market price often diverges from its book value, the accounting figure shown on Chemomab's balance sheet. Smart investors calculate Chemomab Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Chemomab Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Chemomab Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemomab Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.